The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / August / Chinese Trial Validates Scleral Lenses
Health Economics and Policy Refractive News

Chinese Trial Validates Scleral Lenses

Large Chinese trial confirms strong visual outcomes with four-zone scleral lenses for irregular corneas

8/28/2026 3 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Topic Commentary
Objective:

To evaluate the effectiveness and safety of a four-zone scleral lens design for visual rehabilitation in Chinese patients with irregular corneas.

Approach:
  • Study Design: A prospective, multi-center clinical trial involving 138 adults aged 18–65 years with irregular corneas across five Chinese centers.
  • Participants: Patients had irregular corneas due to keratoconus, secondary ectasia, corneal transplantation, or corneal scarring.
  • Follow-up: Participants were fitted with scleral lenses and followed for three months, with data collected from 201 treated eyes.
Key Findings:
  • 97.7% of participants achieved successful visual rehabilitation at one month, defined as an improvement of at least 0.20 logMAR compared with spectacle correction.
  • 98.5% of treated eyes gained two or more lines of vision, with a median improvement of 0.30 logMAR.
  • Fitting efficiency was high, with an average of 1.5 lenses per eye needed for optimal fit.
  • By three months, nearly 75% of participants wore lenses for at least eight hours per day.
  • No serious adverse events were reported, and no cases of corneal infection or new corneal neovascularization occurred.
Limitations:
  • The three-month follow-up limits conclusions regarding long-term safety.
  • The absence of a comparator lens group prevents direct comparisons with other specialty lens modalities.
Sources:
  • Eye Discovery

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: